Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39349 | 0.89 | PDK4 (0.43) | P2RX7USP30USP2SMN1; SMN2ESR2 | |
| SCHEMBL520363 | 0.89 | USP30 (0.42) | P2RX7USP30USP2SMN1; SMN2ESR2 | |
| Carbamic Acid SCHEMBL30167549 | 0.84 | GRM5 (0.41) | P2RX7USP30ESR2NR1H2PDK4 | |
| SCHEMBL20606348 | 0.83 | P2RX7 (0.54) | P2RX7MAPK1 | |
| SCHEMBL24792689 | 0.82 | ESR2 (0.35) | P2RX7USP30ESR2NR1H2PDK4 | |
| SCHEMBL16051476 | 0.82 | USP30 (0.40) | P2RX7USP30USP2SMN1; SMN2GPR119 | |
| SCHEMBL30051523 | 0.81 | P2RX7 (0.44) | P2RX7USP30USP2SMN1; SMN2ESR2 | |
| SCHEMBL986465 | 0.81 | P2RX7 (0.44) | P2RX7USP30USP2SMN1; SMN2ESR2 | |
| SCHEMBL31646076 | 0.81 | P2RX7 (0.53) | P2RX7USP2SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL20131001 | 0.81 | PDK4 (0.40) | USP30USP2SMN1; SMN2ESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250345339-A1 | DOSES AND REGIMENS OF HER2 INHIBITORS | IAMBIC THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| US-9328112-B2 | Tetracyclic CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015119712-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20150218165-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | P2RX7 2914/4885USP30 3406/4885USP2 3623/4885 |
| US-20250345339-A1 | DOSES AND REGIMENS OF HER2 INHIBITORS | ERBB2, EGFR, ERBB3 | P2RX7 3808/4885USP30 2792/4885USP2 2398/4885 |
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, SMN1; SMN2, ATXN10 | P2RX7 4798/4885USP30 3266/4885USP2 4008/4885 |
| US-20150218165-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK1 | P2RX7 2974/4885USP30 2742/4885USP2 2960/4885 |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | P2RX7 770/4885USP30 3702/4885USP2 2835/4885 |
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | P2RX7 386/4885USP30 1830/4885USP2 2791/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | P2RX7 2356/4885USP30 3750/4885USP2 4661/4885 |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | P2RX7 3774/4885USP30 3968/4885USP2 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.